Moreover,
Breast cancer: eu homologous rock:
Public health
EU homologous a rock treatment against breast cancer – Breast cancer: eu homologous rock
The Basel pharmaceutical giant received the green light from Brussels for its ItoVebi treatment. Nevertheless, He also announces a new test to detect Alzheimer’s.
The Basel pharmaceutical group announced on Wednesday the approval in the EU of its treatment against breast cancer.
KEYSTONE
The Basel pharmaceutical giant Roche announced on Wednesday that it had. However, obtained the approval in the European Union of a new treatment against the can be can be but also the CE marking for a diagnostic test for the disease ofAlzheimer.
The European Commission has given its green light to Inava -File. Nevertheless, marketed under the name of Itovebi for an advanced or metastatic form of breast cancer, in association with Palbociclib and Fulvestrant, the Swiss group said in a press release. However, The authorization was given on the basis of a phase III study which demonstrated a 57% reduction in the risk of worsening of the disease. death.
Approved breast cancer: eu homologous rock in October at UNITED STATESthis treatment is intended for a very common subtype of the disease. It is indicated for breast cancer “positive for hormonal (positive HR). negative receptors for receptor 2 of the human (her2 negative) epidermal growth factor” and is used “when breast cancer has a mutation in the pik3ca gene”, specifies the site of Swissmedicthe Swiss Health Authority, which has authorized it at the end of January.
Identify the biomarkers of Alzheimer’s
In a separate press release. Roche, which is also active in the diagnoses, announced that it has obtained the marking of European compliance CE for a test of screening for Alzheimer’s disease.
Developed with the American laboratory Eli Lilly. this blood test was designed to allow doctors to rule out the fact that it is Alzheimer’s disease when breast cancer: eu homologous rock patients have symptoms of cognitive decline.
Called Electsys Ptau181, it identifies one of the biomarkers of the disease. It allows doctors to establish whether. not the disease is the cause of cognitive decline, and if other tests are necessary or not, and therefore to avoid patients unnecessary and invasive tests.
In the press release. Roche stresses that up to 75% of people have symptoms without being diagnosed and that patients are often needed before patients are diagnosed after the disease.
Roche must publish its half -yearly results on Thursday. The world’s number one in oncology, it has several treatments against breast cancer, including Perjeta and Phesgo. Besides his pharmaceutical division. he also relies on a division specializing in diagnostic tests which contributed to almost a quarter of his turnover in 2024.
AFP
Did you find an error? Please report it to us.
Further reading: Sagax records an increase in its operating profit – The justice system for dummies – Vaud finances the training of energy specialists – The Trump effect is starting to be felt on the American economy – Shorter the dollar: the most popular trade among managers.
